{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:17Z","timestamp":1792784597751,"version":"4.5.0"},"reference-count":32,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0531300"],"award-info":[{"award-number":["2024ZD0531300"]}]},{"name":"Healthy Commission of Sichuan Province Medical Science and Technology Program","award":["Project No. 24QNMP093"],"award-info":[{"award-number":["Project No. 24QNMP093"]}]},{"name":"Youth Innovation Project of Sichuan Medical Association","award":["Project No. Q20250004"],"award-info":[{"award-number":["Project No. Q20250004"]}],"id":[{"id":"https:\/\/ror.org\/00ft2kj97","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Luzhou Science and Technology Bureau Project","award":["Project No. 2025JYJ014"],"award-info":[{"award-number":["Project No. 2025JYJ014"]}],"id":[{"id":"https:\/\/ror.org\/04kxx2q73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was partially supported by Sichuan Province Science and Technology Program","award":["Project No. 2026NSFSC0577"],"award-info":[{"award-number":["Project No. 2026NSFSC0577"]}]},{"name":"Special Funding for Cultivation of Defense Talents","award":["Project No. CW202410"],"award-info":[{"award-number":["Project No. CW202410"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast activation protein (FAP)-targeted radioligand therapy is often limited by insufficient tumor uptake and retention. We designed and synthesized two novel aryl fluorosulfate-based covalent FAP-targeted radioligands, [177Lu]Lu-DOTA-mFS-FAP-2286 and [177Lu]Lu-DOTA-mFS-KERERG-FAP-2286, to enhance tumor retention and therapeutic efficacy. Two FAP-targeted radioligands were synthesized, radiolabeled with 177Lu, and evaluated for radiochemical stability. Cellular uptake and internalization were assessed in HEK293-huFAP cells. Biodistribution and serial SPECT imaging were performed in tumor-bearing mice to evaluate tumor targeting and retention. Therapeutic efficacy was investigated in murine xenograft models, and the toxicity of [177Lu]Lu-DOTA-mFS-KERERG-FAP-2286 was assessed. A pilot clinical study including three patients with solid tumors was conducted to preliminarily evaluate the therapeutic potential. All radioligands were successfully labeled with radiochemical purity &amp;gt;95% and showed favorable stability. Cellular assays confirmed the high target specificity. In tumor-bearing mice, [177Lu]Lu-DOTA-mFS-KERERG-FAP-2286 demonstrated significantly higher tumor uptake at 1 h after injection than [177Lu]Lu-DOTA-FAP-2286 and [177Lu]Lu-DOTA-mFS-FAP-2286 (p &amp;lt; 0.01). Treatment with [177Lu]Lu-DOTA-mFS-KERERG-FAP-2286 significantly inhibited tumor growth and showed superior therapeutic efficacy compared with [177Lu]Lu-DOTA-FAP-2286 (p &amp;lt; 0.05). No treatment-related adverse events were observed in the three patients. Primary tumors and metastatic lesions demonstrated high tracer uptake with prolonged retention up to day 10 after injection. [177Lu]Lu-DOTA-mFS-KERERG-FAP-2286 showed favorable tumor targeting, prolonged retention, and potent therapeutic efficacy, supporting its further clinical development for FAP-targeted radioligand therapy (RLT).<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00850","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:34:56Z","timestamp":1788327296000},"page":"5113-5123","source":"Crossref","is-referenced-by-count":0,"title":["Novel Covalent FAP-Targeted Radiotherapy Drug Based on DOTA-FAP-2286 for Enhanced Tumor Uptake, Retention, and Therapeutic Efficacy"],"prefix":"10.1021","volume":"23","author":[{"given":"Shijie","family":"Tang","sequence":"first","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5343-6057","authenticated-orcid":true,"given":"Zhongcai","family":"Jin","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Wu","sequence":"additional","affiliation":[{"name":"The Second People\u2019s Hospital of Neijiang , , No. 470 Xinjiang Road, Dongxing District , , ,","place":["Neijiang, Sichuan, People\u2019s Republic of China, 641000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanggang","family":"Liu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Ai","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":true,"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"National University of Singapore , ,","place":["Singapore, Singapore, 117597"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-5020","authenticated-orcid":true,"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Southwest Medical University , , No. 25 Taiping Street, Jiangyang District , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, People\u2019s Republic of China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"4","key":"2026100509321490600_cit1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1053\/j.semnuclmed.2019.02.002","article-title":"Molecular Imaging and Theranostics-a Multidisciplinary Approach","volume":"49","author":"Farolfi","year":"2019","journal-title":"Semin. Nucl. Med."},{"issue":"2","key":"2026100509321490600_cit2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2967\/jnumed.124.268689","article-title":"Preclinical Evaluation of 68Ga\/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy","volume":"66","author":"Wang","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026100509321490600_cit3","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s00259-026-07766-w","article-title":"Comparative Evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET\/CT in Breast Cancer and Initial Experience with [177Lu]Lu-FAP-2286 Therapy","volume":"53","author":"Liu","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"22","key":"2026100509321490600_cit4","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1158\/1078-0432.CCR-12-0644","article-title":"Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies","volume":"18","author":"Fischer","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"2026100509321490600_cit5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"2026100509321490600_cit6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cpet.2021.03.004","article-title":"Prostate Cancer Theranostics: PSMA Targeted Therapy","volume":"16","author":"Seifert","year":"2021","journal-title":"PET Clin."},{"issue":"23","key":"2026100509321490600_cit7","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026100509321490600_cit8","doi-asserted-by":"publisher","first-page":"0282","DOI":"10.34133\/research.0282","article-title":"Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study","volume":"6","author":"Huang","year":"2023","journal-title":"Research"},{"issue":"1","key":"2026100509321490600_cit9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010212","article-title":"FAP-Targeted Radioligand Therapy with 68Ga\/177Lu-DOTA-2P(FAPI)2 Enhance Immunogenicity and Synergize with PD-L1 Inhibitors for Improved Antitumor Efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"key":"2026100509321490600_cit10","doi-asserted-by":"publisher","first-page":"969731","DOI":"10.3389\/fonc.2022.969731","article-title":"Fibroblast Activation Protein-Based Theranostics in Pancreatic Cancer","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"2026100509321490600_cit11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"2026100509321490600_cit12","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-25-4356","article-title":"Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial","author":"McConathy","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"2026100509321490600_cit13","doi-asserted-by":"publisher","first-page":"111195","DOI":"10.1016\/j.radonc.2025.111195","article-title":"A Preliminary Study on the Safety and Efficacy of 177Lu-FAP-2286 in Gastrointestinal Tumours with Positive FAP Expression","volume":"213","author":"Bai","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"6","key":"2026100509321490600_cit14","first-page":"476","article-title":"Fibroblast Activation Protein (FAP) Targeting Homodimeric FAP Inhibitor Radiotheranostics: A Step to Improve Tumor Uptake and Retention Time","volume":"11","author":"Moon","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"2026100509321490600_cit15","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"2026100509321490600_cit16","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1158\/1535-7163.MCT-24-1108","article-title":"Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites","volume":"24","author":"Wu","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"2026100509321490600_cit17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"11","key":"2026100509321490600_cit18","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical Evaluation of FAP-2286 for Fibroblast Activation Protein Targeted Radionuclide Imaging and Therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"2026100509321490600_cit19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2967\/jnumed.124.268200","article-title":"Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors","volume":"65","author":"Galbiati","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026100509321490600_cit20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026100509321490600_cit21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","article-title":"CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma","volume":"15","author":"Kong","year":"2025","journal-title":"Cancer Discov."},{"issue":"8015","key":"2026100509321490600_cit22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent Targeted Radioligands Potentiate Radionuclide Therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"6","key":"2026100509321490600_cit23","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70198","article-title":"Application of 68Ga- and 177Lu-Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis after Myocardial Infarction","volume":"6","author":"Zhao","year":"2025","journal-title":"MedComm"},{"issue":"8","key":"2026100509321490600_cit24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2018.125","article-title":"Constrained Peptides\u2019 Time to Shine?","volume":"17","author":"Morrison","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"2026100509321490600_cit25","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1016\/j.cell.2022.07.019","article-title":"Accurate de Novo Design of Membrane-Traversing Macrocycles","volume":"185","author":"Bhardwaj","year":"2022","journal-title":"Cell"},{"issue":"1","key":"2026100509321490600_cit26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13550-026-01431-x","article-title":"Preliminary Study of FAP-Targeted Radiopharmaceuticals Based on Covalent Targeting Strategy and Pharmacokinetic Characteristics","volume":"16","author":"Ai","year":"2026","journal-title":"EJNMMI Res."},{"key":"2026100509321490600_cit27","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.6c00249","article-title":"Novel Covalent FAP-Targeted [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 for Improved Pharmacokinetics and Enhanced Tumor Uptake","volume":"23","author":"Jin","year":"2026","journal-title":"Mol. Pharmaceutics"},{"issue":"9","key":"2026100509321490600_cit28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"2026100509321490600_cit29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/RLU.0000000000006271","article-title":"177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma with Multiple Metastases: A Promising Last-Line Treatment Option","volume":"51","author":"Lin","year":"2026","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"2026100509321490600_cit30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11307-020-01539-z","article-title":"A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics","volume":"23","author":"Qiu","year":"2021","journal-title":"Mol. Imag. Biol."},{"key":"2026100509321490600_cit31","doi-asserted-by":"publisher","first-page":"746208","DOI":"10.3389\/fphar.2021.746208","article-title":"Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking","volume":"12","author":"Zou","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"2026100509321490600_cit32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1124\/dmd.119.086579","article-title":"Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics","volume":"47","author":"Basit","year":"2019","journal-title":"Drug Metabol. Dispos."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00850","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5113\/67627846\/mp6c00850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5113\/67627846\/mp6c00850.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:38Z","timestamp":1791208178000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/5113\/5351542\/Novel-Covalent-FAP-Targeted-Radiotherapy-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,28]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00850","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}